How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aripiprazole-desvenlafaxine-succinate-sustained-release.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Aripiprazole + desvenlafaxine succinate sustained release — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Aripiprazole + desvenlafaxine succinate sustained release (Aripiprazole + desvenlafaxine succinate sustained release) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic + serotonin-norepinephrine reuptake inhibitor (SNRI) combination. Area: Ps

marketed Atypical antipsychotic + serotonin-norepinephrine reuptake inhibitor (SNRI) combination Dopamine D2/D3 receptors (aripiprazole); serotonin transporter (SERT) and norepinephrine transporter (NET) (desvenlafaxine) Psychiatry / Mental Health Small molecule Live · refreshed every 30 min

Target snapshot

Aripiprazole + desvenlafaxine succinate sustained release (Aripiprazole + desvenlafaxine succinate sustained release) — Pfizer. Aripiprazole acts as a dopamine D2/D3 receptor partial agonist while desvenlafaxine inhibits serotonin and norepinephrine reuptake, together addressing both psychotic and depressive symptoms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aripiprazole + desvenlafaxine succinate sustained release TARGET	Aripiprazole + desvenlafaxine succinate sustained release	Pfizer	marketed	Atypical antipsychotic + serotonin-norepinephrine reuptake inhibitor (SNRI) combination	Dopamine D2/D3 receptors (aripiprazole); serotonin transporter (SERT) and norepinephrine transporter (NET) (desvenlafaxine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic + serotonin-norepinephrine reuptake inhibitor (SNRI) combination class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aripiprazole + desvenlafaxine succinate sustained release — Competitive Intelligence Brief. https://druglandscape.com/ci/aripiprazole-desvenlafaxine-succinate-sustained-release. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab